Press Releases

 
Press Releases
  Date Title and Summary View
Jan 22, 2015
REDWOOD CITY, Calif., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that Helen Torley, M.B. Ch.B., M.R.C.P., has been appointed to the company's board of directors, bringing the number of directors to nine. Dr. Torley, current president and chief executive officer of Halozyme Therapeutics, brings to the board signif...
Jan 20, 2015
REDWOOD CITY, Calif., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on January 15, 2015, the compensation committee of the company's board of directors granted one new employee an option to purchase 1,200 shares of the company's common stock with a per share exercise price of $31.65...
Jan 9, 2015
REDWOOD CITY, Calif., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on January 2, 2015, the compensation committee of the company's board of directors granted new employee Stephen D. Harrison, the company's senior vice president and chief scientific officer, an option to purchase 75,...
Jan 5, 2015
FDA Not Currently Planning to Hold an Advisory Committee MeetingCompany to Host Webcasted Analyst Day in New York on January 8, 2015 REDWOOD CITY, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action dat...
Dec 17, 2014
REDWOOD CITY, Calif., Dec. 17, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). The addition will take effect as part of the annual re-ranking of the NASDAQ Biotechnology Index upon market open on Monday, December 22, 2014. The NASDAQ...
Dec 16, 2014
REDWOOD CITY, Calif., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that Stephen D. Harrison, M.A., Ph.D., has joined the company as senior vice president and chief scientific officer. Dr. Harrison, a biochemist and molecular biologist, is highly published and has extensive experience leading product-driven research...
Dec 15, 2014
REDWOOD CITY, Calif., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Patiromer for Oral Suspension (Patiromer FOS) for the treatment of hyperkalemia, a serious condition defined as abnormally elevated levels of...
Dec 3, 2014
REDWOOD CITY, Calif., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that John A. Orwin, president and chief executive officer, will present at the Oppenheimer 25th Annual Healthcare Conference on December 10, 2014 at 9:45 a.m. ET. To access the live webcasts and subsequent archived re...
Nov 21, 2014
Treatment with Patiromer FOS Resulted in a Decrease in Elevated Serum Potassium Levels in CKD Patients on RAAS Inhibitors Normal Potassium Levels Maintained More Effectively in Patiromer FOS Treated Patients than with Placebo More Patiromer FOS Treated Patients Able to Continue on RAAS Inhibitor Therapy than with Placebo, a pre...
Nov 20, 2014
REDWOOD CITY, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on November 17, 2014, the compensation committee of the company's board of directors granted new employee Scott Garland, the company's senior vice president and chief commercial officer, an option to purchase 100,00...
Page:
1
... NextLast
= add release to Briefcase